We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Junying Yu, Leading Stem Cell Researcher, Joins Cellular Dynamics International
News

Junying Yu, Leading Stem Cell Researcher, Joins Cellular Dynamics International

Junying Yu, Leading Stem Cell Researcher, Joins Cellular Dynamics International
News

Junying Yu, Leading Stem Cell Researcher, Joins Cellular Dynamics International

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Junying Yu, Leading Stem Cell Researcher, Joins Cellular Dynamics International"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Dr. Yu’s scientific leadership will help to accelerate the company’s efforts toward harnessing the power of induced pluripotent stem (iPS) cells to reproducibly differentiate into essential cell types for drug discovery and development and eventually therapeutic use.

Cellular Dynamics International (CDI) announced the appointment of Junying Yu, Ph.D., as senior research fellow. Her significant body of published research has shown her to be one of the leading stem cell researchers in the world.

Dr. Yu’s scientific leadership will help to accelerate the company’s efforts toward harnessing the power of induced pluripotent stem (iPS) cells to reproducibly differentiate into essential cell types for drug discovery and development and eventually therapeutic use.

The appointment reflects the rapid progress CDI is making in developing commercially available terminal cells derived from iPS cells for drug development. This progress has been highlighted by the recent announcements of two strategic technology in-license arrangements with Mount Sinai School of Medicine and Indiana University-Purdue University Indianapolis and the company’s recent announcement of the generation of iPS cells from normal human blood.

“Dr. Yu strengthens CDI’s scientific team and our ability to exploit our growing patent portfolio,” said Chris Kendrick-Parker, CDI’s Chief Commercial Officer. “Junying is one of the top stem cell researchers in the world, and with her on our team we feel confident that we will be able to provide additional, much needed stem cell research tools and therapies to the preclinical, and eventually clinical, market faster.”

Robert Palay, chairman and chief executive officer of CDI, added, “We are very pleased that, of the many offers Dr. Yu has entertained, she has chosen CDI to further her research and career. Her personal goals align with the company’s goals in being the leader in iPS cell technology, industrializing the process to create the quantity of cells required for use as tools and therapeutics and accelerating the process of bringing personalized medicine to realization.”

Dr. Yu said, “I’m excited to join the team of scientists at CDI working towards personalized therapeutics. In vitro drug testing can be severely limited by the lack of physiologically relevant models arising from non-human animal models or models that do not appropriately reflect the target population. iPS cell technology overcomes these obstacles and offers the promise of generating differentiated cell types from virtually any genetic background.”
Advertisement